Placebo to 200mg masitinib clinical trials

A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 Trial to compare the efficacy and safety of masitinib in combination with standard of care versus placebo in combination with standard of care in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS)

This study is testing a new drug called masitinib for people with Motor Neurone Disease (ALS). It compares masitinib with a dummy pill (placebo) alongside standard treatment to see if it's safe and helps slow down the disease.